Proteina Enters AI Bio Foundry Services... Solving Drug Discovery Bottlenecks

IV Research Releases Analysis Report on Proteina

Independent research firm IV Research announced on October 2, 2026, that Proteina is entering the AI bio foundry service market, leveraging its wet lab capabilities, which are considered a key bottleneck in AI-driven drug discovery. The report did not provide an investment opinion or target price.

IV Research stated, "Proteina's business model is based on new drug development utilizing the protein-protein interaction (PPI) landscape and PPI Pathfinder-based clinical specimen analysis." The PPI landscape business uses a Single-Particle Interaction Detection (SPID) platform to measure key characteristics of antibody candidates on a large scale and to optimize these candidate materials.

Proteina has entered into a co-development and technology transfer option agreement with Samsung Bioepis, which is currently under evaluation. Its in-house pipeline includes PRT-101, a treatment for osteoarthritis, and PRT-1309, a treatment for obesity and metabolic diseases.

The PPI Pathfinder business involves measuring changes in protein-protein interactions in real patient clinical specimens to develop and validate biomarkers. Proteina is currently providing analysis and validation services for BCL-2 blood cancer biomarkers, and is in the process of expanding its scope to include biomarkers for inflammatory and neurological diseases.

Based on these capabilities, the company is expanding its business to include an AI bio foundry service that experimentally validates AI-designed large-scale antibody candidates. IV Research explained, "Developmental suitability characteristics necessary for actual drug development lack sufficient training data, so prediction accuracy is low. This will make wet lab capabilities the key bottleneck in AI drug development."

Proteina plans to offer candidate generation, expression binding strength and productivity assessment, and candidate screening processes—originally built through its PPI landscape business—to external clients as a service. Currently, its analysis capacity stands at approximately 40,000 cases per month, with plans to scale this up to 1 million cases per month by 2028.

IV Research analyzed, "The collaboration with Twist Bioscience will serve as an early example of the AI bio foundry business."

This content was produced with the assistance of AI translation services.